Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study

Pivotal ARISE Study of Erenumab in Episodic Migraine Prevention Met Primary Endpoint People With Episodic Migraine Experience up to 14 Days of Migraine Each Month and Lose a Substantial Part of Their Lives to Migraine Erenumab Co-Developed by Amgen and Novartis

Amgen - Investors - RSS Content